REG - Caledonian Holdings - AlbaCo Signs £25m Regulatory Capital Agreement

Caledonian HoldingsAnnouncement

02/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB8814Ua&default-theme=true

RNS Number : 8814U  Caledonian Holdings PLC  02 March 2026

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon
the publication of this announcement via a Regulatory Information Service,
this inside information is now considered to be in the public domain.

2 March 2026

Caledonian Holdings plc

("Caledonian" or the "Company")

AlbaCo Signs £25m Regulatory Capital Subscription Agreement

Caledonian Holdings plc (AIM: CHP), the AIM-quoted investment company focused
on building a financial services and fintech investment platform, is pleased
to announce that AlbaCo Limited ("AlbaCo"), an investee company of Caledonian,
has signed a subscription agreement for £25 million in respect of its
regulatory capital raise.

Highlights

·    Key investee company AlbaCo, who are looking to become a new UK bank
who will be targeting the SME marketplace, has successfully raised £25
million;

·    Funds raised will enable AlbaCo to support the pre-requisite
regulatory capital requirements, underpinning its application for full
authorisation;

·    Completion of this milestone capital raise represents a major
inflection point in the establishment of a significant new force in UK
banking, subject to regulatory approval by the PRA and FCA;

·    Further justification and valuation under-pinning for Caledonian's
existing 5.47% stake in the Company; and

·    FCA regulatory approval also secured in respect of Caledonian's
separate investment into Aspire Payments Limited.

Keith Barclay, Investment Director of Caledonian, commented:

"The signing of the £25 million regulatory capital subscription agreement
marks a significant step towards AlbaCo receiving full authorisation. Together
with the receipt of FCA change in control approval in relation to Aspire, this
represents continued progress in delivering our strategy of building a
scalable financial services platform."

Background

AlbaCo has signed a subscription agreement for a £25 million regulatory
capital raise which represents a major milestone for AlbaCo and provides
contractual commitment towards the capital required to support its application
for full banking authorisation, subject to full authorisation by the
Prudential Regulatory Authority and AlbaCo shareholder approval.

As previously announced, AlbaCo had been progressing advanced discussions with
investors in relation to securing the regulatory capital necessary to complete
the authorisation process. The execution of the subscription agreement
materially advances AlbaCo's pathway to achieve full authorisation and
provides increased visibility on its funding position.

Following the signing of the subscription agreement, AlbaCo will now proceed
forward with the PRA to obtain an unconditional banking licence following
which it will be in a position to commence trading.

Short-Term Funding Support

AlbaCo has advised its shareholders that, pending full authorisation and
drawdown of the regulatory capital, it requires additional short-term funding
support on a pro rata basis to cover operating costs through to banking
authorisation.

Caledonian has agreed to provide £110,000 of short-term funding to AlbaCo in
addition to the aggregate £2.2 million investment in AlbaCo announced by the
Company on 7 October 2025, 18 December 2025 and 22 January 2026. This support
will be provided on the same structural terms as the aforementioned short-term
capital advanced by the Company and will include the issue of warrants
entitling Caledonian to subscribe for two ordinary shares in AlbaCo for every
one share subscribed pursuant to this funding, exercisable for a period of two
years following completion of AlbaCo's regulatory capital raising. Both the
fees payable and the warrants to be issued to Caledonian in connection with
the short-term funding arrangements will be settled upon completion of the
regulatory capital raising and following full authorisation and drawdown.

Caledonian currently holds 1,500,000 shares in AlbaCo, representing 5.47% of
AlbaCo's existing issued share capital.

FCA Change in Control Approval for Aspire

The Company also confirms that it has received approval from the Financial
Conduct Authority in respect of the previously announced change in control
relating to Aspire Payments Limited ("Aspire").

Receipt of FCA approval represents an important regulatory milestone and
further de-risks the Company's broader strategy of building an integrated
financial services platform anchored around complementary regulated
businesses.

Information on AlbaCo

AlbaCo aims to be a new bank with a clear vision and purpose - to support
small and medium-sized businesses as they develop their aspirations, grow and
realise their potential. AlbaCo aims to help SMEs grow by applying specialist
expertise and insight while forming strong and lasting relationships with its
customers. AlbaCo is not yet open to trade pending full regulatory banking
approval.

For the year ended 29 February 2024, AlbaCo reported a loss after tax of
approximately £8.96 million. As at 29 February 2024, AlbaCo's net assets were
£6.31 million.

For further information, see albacoltd.co.uk (https://www.albacoltd.co.uk/) .

 

For further information, please contact:

 Caledonian Holdings plc                          Tel: +44 (0) 7950 389469

 Jim McColl, Executive Director

 Brent Fitzpatrick, Non-Executive Chairman

   Allenby Capital Limited (Nominated Adviser)    Tel: +44 (0) 20 3328 5656
   Nick Athanas / Piers Shimwell

 AlbR Capital Limited (Broker)                    Tel: +44 (0) 20 7469 0930

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRVFLFBQXLZBBX



            Copyright 2019 Regulatory News Service, all rights reserved